Ondansetron Compared with Granisetron in the Prophylaxis of Cisplatin-lnduced Acute Emesis: A Multicentre Double-Blind, Randomised, Parallel-Group Study
Paul Ruff, B. McQuade(Oxford Research Group), W. Paska(Oxford Research Group), Daniel Vorobiof(The Medical Oncology Centre of Rosebank), John Forster(Oxford Research Group), L. Goedhals, M.E. Butcher(Oxford Research Group), Alison Jones(University of Auckland), R. Pouillart(Institut Curie), R. Brunet(Institut Bergonié), Boaz Bloch(Groote Schuur Hospital), A. Riviére(Centre François Baclesse), C. Martin(Centre Hospitalier Annecy Genevois)
Cited by 123
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
|Journal of Clinical Oncology|2009|850
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
|BMC Cancer|2010|755
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
|Annals of Oncology|2014|603
Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals
|Journal of Clinical Oncology|2005|278